Advanced analytics leverages machine learning (ML), statistical modeling, data mining and visualizations to empower ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACL ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed ...

Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S ...

QuidelOrtho's stock jumped after Q1 2025 earnings beat, but long-term growth remains weak. Check out why QDEL stock is ...

Three Motley Fool contributors believe you can. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

The cells targeted the cancer and eradicated it. Thirteen years later, Whitehead is still cancer-free. Since then, however, ...

Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these ...